Segment reporting (Tables)

12 Months Ended

Jul. 31, 2016

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following financial information represents the operating results of the reportable segments of the Company:

Year ended July 31, 2016	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	70,915			—			—			—		$	70,915
Product revenues		—		$	30,337			—			—			30,337
Royalty and license fee income		—			1,521			—			—			1,521
Total revenues		70,915			31,858			—			—			102,773
Operating costs, expenses and legal settlements, net:
Cost of clinical laboratory services		42,859			—			—			—			42,859
Cost of product revenues		—			14,331			—			—			14,331
Research and development		—			2,720		$	804			—			3,524
Selling, general and administrative		22,882			11,761			—		$	8,943			43,586
Provision for uncollectible accounts receivable		2,375			(39	)		—			—			2,336
Legal fee expense		134			11			—			6,239			6,384
Legal settlements, net		1,500			(58,750	)		—			—			(57,250	)
Total costs, expenses and legal settlements, net		69,750			(29,966	)		804			15,182			55,770
Operating income (loss)		1,165			61,824			(804	)		(15,182	)		47,003
Other income (expense)
Interest		(105	)		47			—			(78	)		(136	)
Other		10			38			—			74			122
Foreign exchange gain		—			(474	)		—			—			(474	)
Income (loss) before taxes	$	1,070		$	61,435		$	(804	)	$	(15,186	)	$	46,515
Depreciation and amortization included above	$	1,676		$	2,091		$	—		$	73		$	3,840
Share-based compensation included in above:
Cost of clinical laboratory services	$	6		$	—		$	—		$	—		$	6
Selling, general and administrative		51			30			—		$	438			519
Total	$	57		$	30		$	—		$	438		$	525
Capital expenditures	$	1,216		$	314		$	—		$	—		$	1,530

Year ended July 31, 2015	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	63,414			—			—			—		$	63,414
Product revenues		—		$	31,690			—			—			31,690
Royalty and license fee income		—			2,495			—			—			2,495
Total revenues		63,414			34,185			—			—			97,599
Operating costs, expenses and legal settlements, net:
Cost of clinical laboratory services		39,589			—			—			—			39,589
Cost of product revenues		—			15,183			—			—			15,183
Research and development		—			2,608		$	742			—			3,350
Selling, general and administrative		20,666			12,168			—		$	8,235			41,069
Provision for uncollectible accounts receivable		2,418			(134	)		—			—			2,284
Legal fee expense		196			(67	)		—			8,659			8,788
Legal settlements, net		—			(11,458	)		—			—			(11,458	)
Total costs, expenses and legal settlements, net		62,869			18,300			742			16,894			98,805
Operating income (loss)		545			15,885			(742	)		(16,894	)		(1,206	)
Other income (expense)
Interest		(86	)		10			—			(169	)		(245	)
Other		28			9			—			58			95
Foreign exchange gain		—			(936	)		—			—			(936	)
Income (loss) before taxes	$	487		$	14,968		$	(742	)	$	(17,005	)	$	(2,292	)
Depreciation and amortization included above	$	1,443		$	2,254		$	3		$	89		$	3,789
Share-based compensation included in above:
Cost of clinical laboratory services	$	5		$	—			—			—		$	5
Research and development		—			2			—			—			2
Selling, general and administrative		43			15			—		$	364			422
Total	$	48		$	17			—		$	364		$	429
Capital expenditures	$	1,557		$	226			—			—		$	1,783

Year ended July 31, 2014	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	58,689			—			—			—		$	58,689
Product revenues		—		$	32,850			—			—			32,850
Royalty and license fee income		—			4,408			—			—			4,408
Total revenues		58,689			37,258			—			—			95,947
Operating costs, expenses and legal settlements, net:
Cost of clinical laboratory services		38,948			—			—			—			38,948
Cost of product revenues		—			15,320			—			—			15,320
Research and development		14			2,350		$	777			—			3,141
Selling, general and administrative		20,460			13,374			—		$	7,967			41,801
Provision for uncollectible accounts receivable		3,115			(52	)		—			—			3,063
Legal fee expense		736			940			—			5,278			6,954
Legal settlements, net		2,000			(5,100	)								(3,100	)
Total costs, expenses and legal settlements, net		65,273			26,832			777			13,245			106,127
Operating (loss) income		(6,584	)		10,426			(777	)		(13,245	)		(10,180	)
Other income (expense)
Interest		(43	)		9			—			(174	)		(208	)
Other		56			95			—			43			194
Foreign exchange gain		—			289			—			—			289
(Loss) income before income taxes	$	(6,571	)	$	10,819		$	(777	)	$	(13,376	)	$	(9,905	)
Depreciation and amortization included above	$	1,415		$	2,455		$	7		$	94		$	3,971
Share-based compensation included in above:
Cost of clinical laboratory services	$	8		$	1			—			—		$	9
Research and development		—			1			—			—			1
Selling, general and administrative		36			6			—		$	542			584
Total	$	44		$	8			—		$	542		$	594
Capital expenditures	$	643		$	195			—			—		$	838

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]

Geographic financial information is as follows:

Net sales to unaffiliated customers:	2016		2015		2014
United States	$	94,016	$	87,875	$	84,389
Switzerland		2,709		3,131		4,130
United Kingdom		1,730		1,904		2,023
Other international countries		4,318		4,689		5,405
Total	$	102,773	$	97,599	$	95,947
Long-lived assets at July 31,
United States	$	18,730	$	19,799
Switzerland		917		1,224
United Kingdom		244		357
Other international countries		197		175
Total	$	20,088	$	21,555

Schedule of Segment Revenue By Geographical [Table Text Block]

The following is a summary of the Life Sciences segment revenues attributable to customers located in the United States and foreign countries:

	2016		2015		2014
United States	$	23,102	$	24,461	$	25,700
Foreign countries		8,756		9,724		11,558
	$	31,858	$	34,185	$	37,258